Outlook Therapeutics, Inc. (OTLK) Fair Value 2026

OTLK · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 10 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-07-15, Outlook Therapeutics, Inc. (OTLK) trades at $1.56, approximately 325% above CirclFi’s Bayesian DCF fair value of $0.37. QOC: 4.3/10. Value Trap Risk: 36/100 (LOW). 10/13 models active.

Key Facts

Ticker
OTLK
Price
$1.56
Quality Score
4.3/10
Value Trap Risk
36/100
Models Active
10/13
Last Updated
Strength: 10 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

Is Outlook Therapeutics, Inc. (OTLK) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Outlook Therapeutics, Inc. (OTLK) appears overvalued as of : the median of 10 independent fair value estimates is $0.23, 85.5% below the current price of $1.56. Estimates range from $0.01 to $1.71. OTLK scores 4.3/10 on fundamental quality and 36/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Outlook Therapeutics, Inc. Stock in 2026? →

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($1.56)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.37 -76.5%
Earnings Power Value
Medium Conviction
 $0.06 -95.8%
CUCE Ensemble
Low Conviction
 $0.61 -61.2%
First Chicago
Medium Conviction
 $0.08 -94.6%

Unlock the Full Matrix

Access 6 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is Outlook Therapeutics, Inc. (OTLK) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Outlook Therapeutics, Inc.'s intrinsic value is estimated at $0.48. Trading at its current price of $1.56, the valuation engine raises significant caution: 9 of 10 models flag downside risk, projecting an average implied return of -69.0%. Model dispersion is worth noting: PWERM targets $1.71 (+9.3%), versus ML-RIV at $0.01 (-99.1%). This +108.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About OTLK?

10 of 13 models are currently active for OTLK. Of these, 1 model suggests upside while 9 models suggest overvaluation. The Bayesian DCF estimates OTLK's intrinsic value at $0.37, implying -76.5% downside from the current price. See which stocks rank higher →

How Does OTLK Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, OTLK ranks #104 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Outlook Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is OTLK a Value Trap?

CirclFi's Value Trap algorithm assigns OTLK a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Outlook Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Outlook Therapeutics, Inc. earns a quality score of 4.3/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +108.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every OTLK valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across OTLK's 10 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Outlook Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Outlook Therapeutics, Inc.

What is Outlook Therapeutics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Outlook Therapeutics, Inc. (OTLK) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.37. The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is OTLK overvalued or undervalued right now?

At $1.56, 1 of 10 active models suggest OTLK may be undervalued, while 9 indicate potential overvaluation. The median of all 10 fair value estimates is $0.23, 85.5% below the current price of $1.56 — a consensus view that OTLK is overvalued. The assessment depends on which methodology best fits Outlook Therapeutics, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 4.3 mean for OTLK?

Outlook Therapeutics, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on OTLK?

CirclFi analyzes OTLK with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is OTLK a value trap in 2026?

Outlook Therapeutics, Inc.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Outlook Therapeutics, Inc. (OTLK) has a median fair value of $0.23 — 85.5% below the current price of $1.56 — as of 2026-07-15.” Source: circlfi.com/stock/OTLK/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on OTLK.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access